During the past decade, The Aurum Institute: Tembisa Clinical Research Centre conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 6 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 6 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Aurum Institute: Tembisa Clinical Research Centre" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 5 trials, followed by "The Aurum Institute NPC" with 4 trials sponsored, "Gilead Sciences" with 3 trials sponsored, "Janssen Vaccines & Prevention B.V." with 2 trials sponsored and "Wits Health Consortium (Pty) Ltd" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Aurum Institute: Tembisa Clinical Research Centre" #1 collaborator was "Bio Analytical Research Corporation" with 2 trials as a collaborator, "BioVac" with 2 trials as a collaborator, "Biocair" with 2 trials as a collaborator, "Clinical Laboratory Services" with 2 trials as a collaborator and "Dis-Chem Pharmacy" with 2 trials as a collaborator. Other collaborators include 33 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "The Aurum Institute: Tembisa Clinical Research Centre" are "HIV Infections" (7 trials), "Pre-Exposure Prophylaxis of HIV Infection" (2 trials), "Tuberculosis" (2 trials), "Tuberculosis, Pulmonary" (2 trials) and "Acquired Immune Deficiency Syndrome (AIDS)" (1 trials). Many other conditions were trialed in "The Aurum Institute: Tembisa Clinical Research Centre" in a lesser frequency.

Most popular intervention types in "The Aurum Institute: Tembisa Clinical Research Centre" are "Biological" (10 trials), "Drug" (7 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "ALVAC-HIV (vCP2438)" (2 trials), "Bivalent Subtype C gp120/MF59" (2 trials), "DNA-HIV-PT123 vaccine" (2 trials) and "F/TAF" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Aurum Institute: Tembisa Clinical Research Centre" are 13 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Aurum Institute: Tembisa Clinical Research Centre". 1 are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in The Aurum Institute: Tembisa Clinical Research Centre, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in The Aurum Institute: Tembisa Clinical Research Centre, 5 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".